9001-28-9

Basic information

• Product Name: HUMAN FACTOR IX
• Synonyms: ahf-b;antihemophilicfactorb;bloodcoagulationfactorix;plasmathromboplastincomponent;ptc(bloodcoagulationfactor);PTC, HUMAN;PLASMA THROMBOPLASTIN COMPONENT, HUMAN;CHRISTMAS FACTOR
• CAS NO: 9001-28-9
• Molecular Weight: 0
• EINECS: 232-594-4
• Product Categories: proteins
• Mol File: 9001-28-9.mol
• Article Data: 0

Chemical Properties

• Appearance: /lyophilized powder
• Storage Temp.: −20°C
• CAS DataBase Reference: HUMAN FACTOR IX(CAS DataBase Reference)
• NIST Chemistry Reference: HUMAN FACTOR IX(9001-28-9)
• EPA Substance Registry System: HUMAN FACTOR IX(9001-28-9)

Safety Data

• WGK Germany: 3
• RTECS: EC6045000
• Hazardous Substances Data: 9001-28-9(Hazardous Substances Data)

Usage

Description

Human Factor IX is a plasma zymogen that plays a crucial role in the blood coagulation system. It is involved in the activation of the coagulation cascade, leading to the formation of blood clots and preventing excessive bleeding. Human Factor IX is essential for maintaining hemostasis and preventing bleeding disorders.

Uses

Used in Medical Research:
Human Factor IX is used as a key factor in studies of blood coagulation systems for understanding the mechanisms of clot formation and the role of various factors in the coagulation cascade.
Used in Portal Vein Thrombosis Studies:
Human Factor IX is used as a biomarker in studies of portal vein thrombosis (PVT) in hepatocellular carcinoma (HCC) patients. Abnormalities in Factor IX have been found to contribute to PVT, providing insights into the pathophysiology of the condition and potential therapeutic targets.
Used in Inflammatory Bowel Disease Research:
Human Factor IX is used as a research tool in studies of changes in the coagulation system in patients with inflammatory bowel disease (IBD). This helps in understanding the interplay between the coagulation system and inflammatory processes in IBD, potentially leading to the development of novel therapeutic approaches.
Used in Hemophilia B Treatment:
Human Factor IX is used as a therapeutic agent for the treatment of Hemophilia B, a genetic bleeding disorder caused by a deficiency or dysfunction of Factor IX. Replacement therapy with recombinant or plasma-derived Factor IX helps in managing the symptoms and preventing bleeding episodes in Hemophilia B patients.

World Health Organization (WHO)

Factor IX, a naturally occurring plasma protein fraction, is a vital component of the normal blood clotting mechanism which is deficient in haemophiliacs who require replacement therapy for both the treatment and prevention of bleeding. Factor IX is extracted from the pooled plasma of a large number of donors and is presented as a concentrate. It has been recognized since 1984 that some viruses, and particularly the HIV (AIDS virus) could be transmitted to haemophiliacs from such preparations. As a result many regulatory authorities have issued new directives for the manufacture of blood products that avert this danger, by requiring the introduction of specific antiviral treatment measures during the manufacturing process. Manufacturers have withdrawn pre-existing preparations.